吲哚胺-2,3-双加氧酶-1在肿瘤免疫及治疗中的研究现状  

Current status of indoleamine-2, 3-dioxygenase-1 in tumor immunity and treatment

作　　者：梅世文 刘正[1] 刘骞[1] Mei Shiwen;Liu Zheng;Liu Qian(Department of Colorectal Surgery,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100020,China)

机构地区：[1]国家癌症中心,中国医学科学院肿瘤医院结直肠外科,北京100020

出　　处：《肿瘤研究与临床》2020年第9期597-600,共4页Cancer Research and Clinic

基　　金：国家重点研发计划"重大慢性非传染性疾病防控研究"重点专项(2019YFC1315705);中国癌症基金会北京希望马拉松专项基金(LC2017L07);中国医学科学院医学与健康科技创新工程项目(2017-12M-1-006)。

摘　　要：近年来,程序性死亡受体1(PD-1)/程序性死亡受体配体1(PD-L1)抑制剂在免疫治疗方面取得了一定疗效,但对提高患者远期生存作用方面仍有限,肿瘤免疫治疗的有效性一方面取决于正向作用的自身免疫系统对肿瘤高效的识别和特异性免疫,另一方面取决于负向作用的肿瘤免疫逃逸。吲哚胺-2,3-双加氧酶-1(IDO1)作为色氨酸代谢途径中重要的限速酶,其高表达可以发挥免疫逃逸及抑制作用,有望为免疫治疗提供新的靶点和途径,文章对IDO1在恶性肿瘤中的研究现状和进展进行综述。In recent years,programmed death 1(PD-1)/programmed death-ligand 1(PD-L1)inhibitors have achieved some efficacies in immunotherapy,but they are still limited in improving long-term survival.The effectiveness of tumor immunotherapy on the one hand depends on the efficient recognition of tumors and specific immunity by the positive acting autoimmune system,on the other hand it depends on the negative acting tumor immune escape.Indoleamine-pyrrole 2,3-dioxygenase-1(IDO1)as an important rate-limiting enzyme in the metabolic pathway of tryptophan,has attracted scholars'attention.And it has been found that its high expression can develop an immune escape and inhibition,and the research of IDO1 in tumor immunity is expected to provide new targets and approaches for immunotherapy.The paper reviews the current research status and progress of IDO1 in malignant tumors.

关 键 词：肿瘤 免疫疗法 吲哚胺-吡咯2 3-双加氧酶 

分 类 号：R730.51[医药卫生—肿瘤]